◆KainosMed=Signed a technology transfer agreement for the neurological disease treatment KM819 with the U.S. company FAScinate Therapeutics, Inc.
◆Hanamicron=Clarified that it is reviewing mid- to long-term business cooperation regarding reports on the D-RAM post-process consignment contract with SK Hynix.
◆Amicogen=Decided on a new facility investment worth 61 billion KRW to produce raw materials for biopharmaceuticals and develop biopharmaceutical CDMO.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- "Russia Launches Large-Scale Nuclear Drills During Putin's Visit to China"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
◆Caregen=KOSDAQ Market Headquarters announced a preliminary designation as an unfaithful disclosure company due to reversal of disclosure related to termination of a single sales and supply contract.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
